Kaposi's sarcoma in rheumatic diseases
Objective: To review the clinical features and outcome of all reported cases of Kaposi's sarcoma in patients with rheumatic diseases. Methods: In addition to our patient, we identified cases from a Medline search between the years 1966 and 2002. Cases associated with human immunodeficiency viru...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-0037393824&partnerID=40&md5=a5365a377b284874c236dc6f4959fa07 http://www.ncbi.nlm.nih.gov/pubmed/12701043 http://cmuir.cmu.ac.th/handle/6653943832/3398 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
id |
th-cmuir.6653943832-3398 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-33982014-08-30T02:26:05Z Kaposi's sarcoma in rheumatic diseases Louthrenoo W. Kasitanon N. Mahanuphab P. Bhoopat L. Thongprasert S. Objective: To review the clinical features and outcome of all reported cases of Kaposi's sarcoma in patients with rheumatic diseases. Methods: In addition to our patient, we identified cases from a Medline search between the years 1966 and 2002. Cases associated with human immunodeficiency virus infection were excluded. Results: Including our patient, there were a total of 25 cases reported (11 men and 14 women). Rheumatoid arthritis was present in 8 cases, polymyositis/dermatomyositis in 5, vasculitis syndromes in 5, systemic lupus erythematosus in 3, polymyalgia rheumatica in 2, and 1 each of undifferentiated connective tissue disease and Behcet disease. All but 1 patient had been given systemic corticosteroids for a duration that ranged from 6 weeks to 22 years, and immunosuppressive drugs from 25 days to 3.5 years. The Kaposi's lesions usually involved the skin on the extremities; internal organ involvement occurred in 7 cases. Most lesions responded to a decreasing dosage of corticosteroids and immunosuppressive drugs, or to the administration of radiation or cytotoxic therapy. Six patients died, 4 of which were related to the progression of Kaposi's sarcoma. Conclusion: Kaposi's sarcoma in patients with rheumatologic conditions is rare. The clinical features are similar to those with classical Kaposi's sarcoma. Tumor regression usually occurs with decreasing corticosteroids and/or immunosuppressive drugs, local irradiation, or cytotoxic therapy. Copyright 2003, Elsevier Inc. All rights reserved. 2014-08-30T02:26:05Z 2014-08-30T02:26:05Z 2003 Article 00490172 10.1053/sarh.2002.50000 12701043 SAHRB http://www.scopus.com/inward/record.url?eid=2-s2.0-0037393824&partnerID=40&md5=a5365a377b284874c236dc6f4959fa07 http://www.ncbi.nlm.nih.gov/pubmed/12701043 http://cmuir.cmu.ac.th/handle/6653943832/3398 English |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
language |
English |
description |
Objective: To review the clinical features and outcome of all reported cases of Kaposi's sarcoma in patients with rheumatic diseases. Methods: In addition to our patient, we identified cases from a Medline search between the years 1966 and 2002. Cases associated with human immunodeficiency virus infection were excluded. Results: Including our patient, there were a total of 25 cases reported (11 men and 14 women). Rheumatoid arthritis was present in 8 cases, polymyositis/dermatomyositis in 5, vasculitis syndromes in 5, systemic lupus erythematosus in 3, polymyalgia rheumatica in 2, and 1 each of undifferentiated connective tissue disease and Behcet disease. All but 1 patient had been given systemic corticosteroids for a duration that ranged from 6 weeks to 22 years, and immunosuppressive drugs from 25 days to 3.5 years. The Kaposi's lesions usually involved the skin on the extremities; internal organ involvement occurred in 7 cases. Most lesions responded to a decreasing dosage of corticosteroids and immunosuppressive drugs, or to the administration of radiation or cytotoxic therapy. Six patients died, 4 of which were related to the progression of Kaposi's sarcoma. Conclusion: Kaposi's sarcoma in patients with rheumatologic conditions is rare. The clinical features are similar to those with classical Kaposi's sarcoma. Tumor regression usually occurs with decreasing corticosteroids and/or immunosuppressive drugs, local irradiation, or cytotoxic therapy. Copyright 2003, Elsevier Inc. All rights reserved. |
format |
Article |
author |
Louthrenoo W. Kasitanon N. Mahanuphab P. Bhoopat L. Thongprasert S. |
spellingShingle |
Louthrenoo W. Kasitanon N. Mahanuphab P. Bhoopat L. Thongprasert S. Kaposi's sarcoma in rheumatic diseases |
author_facet |
Louthrenoo W. Kasitanon N. Mahanuphab P. Bhoopat L. Thongprasert S. |
author_sort |
Louthrenoo W. |
title |
Kaposi's sarcoma in rheumatic diseases |
title_short |
Kaposi's sarcoma in rheumatic diseases |
title_full |
Kaposi's sarcoma in rheumatic diseases |
title_fullStr |
Kaposi's sarcoma in rheumatic diseases |
title_full_unstemmed |
Kaposi's sarcoma in rheumatic diseases |
title_sort |
kaposi's sarcoma in rheumatic diseases |
publishDate |
2014 |
url |
http://www.scopus.com/inward/record.url?eid=2-s2.0-0037393824&partnerID=40&md5=a5365a377b284874c236dc6f4959fa07 http://www.ncbi.nlm.nih.gov/pubmed/12701043 http://cmuir.cmu.ac.th/handle/6653943832/3398 |
_version_ |
1681420040615755776 |